Cargando…

Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases

Diabetic kidney disease (DKD), a serious diabetic complication, results in podocyte loss and proteinuria through NADPH oxidases (NOX)-mediated ROS production. DUOX1 and 2 are NOX enzymes that require calcium for their activation which enters renal cells through the pivotal TRPC channels. Hypoglycemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Youssef, Natalie, Noureldein, Mohamed, Njeim, Rachel, Ghadieh, Hilda E., Harb, Frederic, Azar, Sami T., Fares, Nassim, Eid, Assaad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533165/ https://www.ncbi.nlm.nih.gov/pubmed/34680477 http://dx.doi.org/10.3390/biomedicines9101360

Ejemplares similares

Urinary 20-HETE: A prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney disease
por: Houeiss, Pamela, et al.
Publicado: (2022)

Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease
por: Njeim, Rachel, et al.
Publicado: (2023)

Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats
por: El Amin Ali, Amani M., et al.
Publicado: (2022)

Immunomodulatory Approaches in Diabetes-Induced Cardiorenal Syndromes
por: Ammar, Lama A., et al.
Publicado: (2021)

Crosstalk Between SMPDL3b and NADPH Oxidases Mediates Radiation-Induced Damage of Renal Podocytes
por: Azzam, Patrick, et al.
Publicado: (2021)

COVID-19 and diabetes mellitus: how one pandemic worsens the other
por: Azar, William S., et al.
Publicado: (2020)

Mechanisms of Podocyte Injury in Diabetes: Role of Cytochrome P450 and NADPH Oxidases
por: Eid, Assaad A., et al.
Publicado: (2009)

Rompin' at the Reno /
por: Carter, Benny
Publicado: (1960)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy
por: El Khoury, Mirella, et al.
Publicado: (2023)

NADPH Oxidase and Neurodegeneration
por: Hernandes, Marina S, et al.
Publicado: (2012)

NADPH Oxidase 1 and NADPH Oxidase 4 Have Opposite Prognostic Effects for Patients with Hepatocellular Carcinoma after Hepatectomy
por: Ha, Sang Yun, et al.
Publicado: (2016)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

NADPH Oxidases and Their Role in Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2020)

NADPH Oxidases in Pain Processing
por: Kallenborn-Gerhardt, Wiebke, et al.
Publicado: (2022)

NADPH Oxidases in Aortic Aneurysms
por: Salmon, Morgan
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Localization and Interaction between Kinin B1 Receptor and NADPH Oxidase in the Vascular System of Diabetic Rats
por: Haddad, Youssef, et al.
Publicado: (2017)

The contribution of TRPC1, TRPC3, TRPC5 and TRPC6 to touch and hearing
por: Sexton, Jane E., et al.
Publicado: (2016)

Influence of intermittent fasting on prediabetes-induced neuropathy: Insights on a novel mechanistic pathway
por: Dannawi, Maya, et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Combining Neprilysin Inhibitor With AT(2)R Agonist Is Superior to Combination With AT(1)R Blocker in Providing Reno-Protection in Obese Rats
por: Gray, Elizabeth Alana, et al.
Publicado: (2022)

HIF-1α Activation by Intermittent Hypoxia Requires NADPH Oxidase Stimulation by Xanthine Oxidase
por: Nanduri, Jayasri, et al.
Publicado: (2015)

Natural Compounds as Modulators of NADPH Oxidases
por: Maraldi, Tullia
Publicado: (2013)

NADPH Oxidases and Mitochondria in Vascular Senescence
por: Salazar, Gloria
Publicado: (2018)

NADPH oxidases: Current aspects and tools
por: Schröder, Katrin
Publicado: (2020)

Architecture of the NADPH oxidase family of enzymes
por: Ogboo, Blessing C., et al.
Publicado: (2022)

(Poly)phenols and the regulation of NADPH oxidases
por: Fraga, Cesar G., et al.
Publicado: (2023)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

ROLE OF RAC-1 DEPENDENT NADPH OXIDASE IN THE GROWTH OF PANCREATIC CANCER
por: Du, Juan, et al.
Publicado: (2010)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Serum Level of Xanthine Oxidase, Uric Acid, and NADPH Oxidase 1 in Stage I of Multiple Myeloma
por: Kohsari, Maryam, et al.
Publicado: (2020)

CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of β-Thalassemia through an Increase in 20-HETE Activity
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2021)

TRPC3 Regulates Islet Beta‐Cell Insulin Secretion
por: Rached, Gaëlle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g47g3o2ah2hm67u5lkn7glvac6